Omaha, NE 的 非霍奇金淋巴瘤 臨床試驗
14 項針對 非霍奇金淋巴瘤 的研究正在 Omaha(約 30 英里範圍內)及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本(英文)
正在為研究招募對象嗎?將此頁面置頂展示 — $99 / 30 天 →
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
招募中2 期
- University of Nebraska Medical Center, Omaha
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
招募中1 期
- The University of Nebraska Medical Center, Omaha
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
招募中1/2 期
- Local Institution - 0124, Omaha
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
招募中2 期
- Nebraska Cancer Specialists, Omaha
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
招募中1/2 期
- University of Nebraska Medical Center, Omaha
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
招募中1 期
- University of Nebraska Medical Center, Omaha
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
招募中3 期
- University of Nebraska Medical Center (UNMC), Omaha
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
招募中觀察性研究
- University of Nebraska Medical Center, Omaha
Halt Aging in Survivors of Blood Cancers
招募中
- University of Nebraska Medical Center, Omaha
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
招募中1/2 期
- Nebraska Cancer Specialists, Omaha
- University of Nebraska Medical Center, Omaha
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
招募中1/2 期
- Fred and Pamela Buffett Cancer Center, Omaha
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
招募中4 期
- University Of Nebraska Medical Center, Omaha
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
招募中4 期
- University Of Nebraska Medical Center, Omaha
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Omaha
其他城市的 非霍奇金淋巴瘤 試驗
- Houston, TX31 項研究
- New York City, NY31 項研究
- Boston, MA26 項研究
- Nashville, TN21 項研究
- Philadelphia, PA20 項研究
- Baldwin Park, CA19 項研究
- Washington, DC18 項研究
- Chicago, IL18 項研究
- Milwaukee, WI18 項研究
- Atlanta, GA18 項研究
- Columbus, OH18 項研究
- Dallas, TX17 項研究
Omaha 的其他研究
- 前列腺癌27 項研究
- 非小細胞肺癌24 項研究
- 乳癌22 項研究
- 癌症(所有類型)18 項研究
- 大腸直腸癌18 項研究
- 多發性骨髓瘤16 項研究
- 卵巢癌14 項研究
- 胰臟癌14 項研究
- 轉移性癌症13 項研究
- 頭頸部鱗狀細胞癌13 項研究
- 心臟衰竭13 項研究
- 黑色素瘤12 項研究
資料來源:ClinicalTrials.gov,擷取日期 2026年10月6日。各研究自行設定資格標準;由研究團隊決定參與者資格。